Our CEO Susan Greenfield and Operations Direction Sara Garcia-Rates, joined Xenopat for a face-to-face meeting in Barcelona where they shared the progress made for the Tecniospring Industry project “Development of a T14 Inhibitor for Treatment of ColoRectal Cancer”, and explored the possibilities for future projects that could sprout from this collaboration.
LATEST NEWS
- Baroness Greenfield to attend NeuRA (Neuroscience Research Australia) Sydney in May 2024!
- Baroness Greenfield to speak at the Early Career Dementia Researchers Retreat in June 2024!
- Transforming Alzheimer’s Disease Detection – Collaboration with Aptamer Group
- THENA Capital podcast with Baroness Susan Greenfield
- Neuro-Bio and Aptamer enter the second phase of Alzheimer’s test development